Archer Aviation (NYSE:ACHR) presents an intriguing conundrum for investors, offering both enormous promise but also plenty of ...

Since its opening in 2017, the ADC in Tallahassee has worked with customers to develop and test new HVAC/R products and ...

One of the most effective ways to attract new talent is by establishing clear, accessible pathways into the trades. That’s ...

Wondering if Archer Aviation at around $8.30 is a hidden bargain or a hype fueled high flyer? This breakdown will help you decide whether the current price really makes sense. The stock has been ...

Archer Aviation Inc. (NYSE:ACHR) is one of the Best Aerospace Stocks to Buy According to Analysts. On December 9, Archer ...

Amgen receives US FDA approval for Uplizna to treat Adults with generalized myasthenia gravis: Thousand Oaks, California Saturday, December 13, 2025, 11:00 Hrs [IST] Amgen announc ...

In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.

The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...

Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...